Olema Pharmaceuticals, INC 8-K filings

Olema Pharmaceuticals announces the appointment of Jason O'Byrne as Chief Financial Officer, bringing extensive experience in biopharmaceutical finance and capital markets.

Olema Pharmaceuticals and Bayer Consumer Care AG have entered into a clinical trial collaboration to evaluate Olema's OP-3136 in combination with Bayer's NUBEQA for metastatic castration-resistant prostate cancer.

Olema Pharmaceuticals announced encouraging preliminary clinical data from its Phase 1 study of OP-3136, a KAT6 inhibitor, showing good tolerability and anti-tumor activity across multiple solid tumor types.

Olema Pharmaceuticals announced its first quarter 2026 financial and operating results, highlighting progress in its breast cancer pipeline with key clinical trial data expected soon.

Olema Pharmaceuticals has entered into a seven-year lease agreement for new office and lab space in South San Francisco.

Olema Pharmaceuticals announced the appointment of Dr. Prakash Raman to its Board of Directors, effective April 28, 2026, bringing extensive biopharmaceutical industry experience.

Olema Pharmaceuticals reported its full-year 2025 financial and operating results, highlighting progress in its pivotal Phase 3 trials for palazestrant and a strengthened balance sheet.

Olema Pharmaceuticals' Chief Operating and Financial Officer, Shane Kovacs, is departing, with CEO Sean Bohen assuming interim financial duties.

Olema Pharmaceuticals announced preliminary unaudited cash exceeding $500 million and provided updates on its advanced breast cancer drug pipeline, including pivotal Phase 3 trials for palazestrant.

Olema Pharmaceuticals, Inc. announced a follow-on public offering of 10 million shares of common stock at $19.00 per share, aiming to raise approximately $190 million in gross proceeds.

Olema Pharmaceuticals, Inc. announced the termination of its at-the-market (ATM) prospectus, effective November 18, 2025, halting further common stock sales under the current agreement.

Olema Pharmaceuticals reported its third-quarter 2025 financial and operating results, highlighting significant progress in its breast cancer clinical programs and a new collaboration with Pfizer.

Olema Pharmaceuticals announced encouraging Phase 1b/2 trial data for palazestrant combined with ribociclib in ER+/HER2metastatic breast cancer, showing compelling progression-free survival and favorable tolerability.

Olema Pharmaceuticals announced a new clinical trial agreement with Pfizer to evaluate palazestrant combined with atirmociclib for ER+/HER2metastatic breast cancer.

Olema Pharmaceuticals reports Q2 2025 results, advancing pivotal Phase 3 trials for palazestrant and initiating a Phase 1 study for OP-3136.

Olema Pharmaceuticals, Inc. announced that its stockholders approved all three proposals, including the election of three Class II directors, advisory approval of executive compensation, and ratification of Ernst & Young LLP as its independent auditor, at its annual meeting held on June 10, 2025.

Olema Pharmaceuticals announced its Q1 2025 financial results and highlighted progress in its palazestrant and OP-3136 clinical programs for breast cancer and other solid tumors.

Olema Oncology announces financial results for 2024, highlighting progress in clinical trials and a $250 million equity private placement.

Olema Pharmaceuticals is progressing its clinical pipeline with palazestrant, a potential best-in-class therapy for ER+/HER2breast cancer, and OP-3136, a KAT6 inhibitor, while preparing for a potential U.S. commercial launch in 2027.

Olema Pharmaceuticals is advancing its pipeline of breast cancer therapies, highlighted by palazestrant and OP-3136, with key clinical trials and a potential commercial launch planned for 2027.

Olema Pharmaceuticals enters into exchange agreements with major investors to exchange common stock for pre-funded warrants, aiming to streamline its capital structure.

Olema Pharmaceuticals has received FDA clearance for its new drug OP-3136 and reported promising results from a Phase 1b/2 study of palazestrant in combination with ribociclib for breast cancer.

Olema Pharmaceuticals has announced a $250 million private placement and a clinical trial collaboration with Novartis to advance its breast cancer treatment pipeline.

Olema Pharmaceuticals reported its Q3 2024 financial results, highlighted by progress in clinical trials for palazestrant and the advancement of their KAT6 inhibitor program.

Olema Pharmaceuticals is progressing its breast cancer programs, including a KAT6 inhibitor and palazestrant, with upcoming data presentations and clinical trial initiations.

Olema Pharmaceuticals announced positive interim clinical results for palazestrant in combination with ribociclib, progress on their KAT6 inhibitor, and a cash balance of $239.1 million as of June 30, 2024.

Olema Pharmaceuticals has amended its loan agreement, increasing the potential borrowing amount to $100 million and extending the maturity date to July 1, 2028.

Olema Pharmaceuticals held its annual meeting on June 13, 2024, where stockholders elected three Class I directors, approved executive compensation on an advisory basis, and ratified the selection of Ernst & Young LLP as the independent auditor for 2024.

Olema Pharmaceuticals reported promising interim results from a Phase 1b/2 clinical study of palazestrant in combination with ribociclib for ER+/HER2metastatic breast cancer, showing a high clinical benefit rate and good tolerability.

Olema Pharmaceuticals reported its Q1 2024 financial results, highlighted clinical trial progress, and provided updates on its drug development programs.